NPI: 1902534845 · CHICAGO, IL 60660 · Clinical Medical Laboratory · NPI assigned 08/09/2022
Authorized official KHAN, MUHAMMAD controls 14+ related entities in our dataset. Read more
| Authorized Official | KHAN, MUHAMMAD (AUTHORIZED OFFICIAL) |
| NPI Enumeration Date | 08/09/2022 |
Other providers sharing the same authorized official: KHAN, MUHAMMAD
| Provider | City | State | Total Paid |
|---|---|---|---|
| AMERICAN INSTITUTE OF MEDICAL SOLUTIONS, LLC | DAYTON | OH | $22.54M |
| MUHAMMAD J.S.KHAN MD,PC | ELMHURST | NY | $971K |
| SAGINAW VALLEY MEDICAL CARE PLC | SAGINAW | MI | $842K |
| AMERIBEST HOME CARE | CINCINNATI | OH | $478K |
| TRICITY INTERNISTS | SAGINAW | MI | $358K |
| UMMAH RELIEF INTERNATIONAL | ELGIN | IL | $328K |
| M N KHAN PC | BLOOMFIELD HILLS | MI | $228K |
| SOUTHWEST KANSAS CARDIOLOGY, LLC | DODGE CITY | KS | $210K |
| EPIC HEART & VASCULAR CENTER PLLC | HOUSTON | TX | $91K |
| KHAN MEDICAL CLINIC, PLLC | COTULLA | TX | $58K |
| DALLAS MD ASSOCIATES LLC | FRISCO | TX | $43K |
| CENTRAL FLORIDA INTERNISTS, INC. | SAINT CLOUD | FL | $40K |
| MIDMICHIGAN GERIATRICS PLC | SAGINAW | MI | $26K |
| COMPREHENSIVE POSTACUTE CARE PLLC | TACOMA | WA | $5K |
| Year | Claims | Total Paid |
|---|---|---|
| 2024 | 48,177 | $4.34M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 0240U | 22,311 | 3,372 | $3.04M | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 21,833 | 3,319 | $877K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 2,017 | 1,359 | $335K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2,016 | 1,359 | $93K |